Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a burgeoning social and healthcare problem. Cholinesterase inhibitors (ChEIs) are employed for symptomatic treatment of AD, but often elicit adverse drug reactions (ADRs). Herein, the potency of the ChEIs, donepezil, tacrine, berberine, and galantamine to inhibit human or Torpedo californica acetylcholinesterase (tcAChE) proteins were evaluated. The efficacy of dual-drug combinations to inhibit human AChE directly and within differentiated neurons was also quantified. ChEI potency was in the order: donepezil > tacrine > berberine > galantamine for both AChEs. Dual-drug combinations of berberine and tacrine (BerTac), berberine and galantamine (BerGal), and tacrine and donepezil (TacDon) all produced synergistic outcomes for AChE inhibition. Donepezil and berberine (DonBer) and tacrine and galantamine (TacGal) elicited antagonistic responses. Donepezil and galantamine (DonGal) was synergistic for human AChE but antagonistic for tcAChE. After application of dual-drug combinations to neuronal cells, BerTac, BerGal, DonGal, and DonBer all showed synergistic inhibition of AChE, TacDon additive, and TacGal antagonistic effects. BerGal produced the most potent synergism and reduced total drug dose by 72%. Individual ChEIs or dual-drug combinations were relatively non-toxic to neuronal cells, and only reduced cell viability at concentrations two–three orders of magnitude greater than that required to inhibit AChE. In summary, dual-drug combinations of ChEIs potentially represent a novel means of AD patient treatment, with reduced and more cost-effective drug dosing, and lowered likelihood of ADRs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil (4) and galantamine (6), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of cholinergic drugs in AD, including efficacy, tolerability, and safety.402,408”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [408]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126 · cited 1×
“A microtiter plate version of the Ellman’s assay was used to determine the activity of human and Torpedo californica acetylcholinesterase enzymes [27].”
Method2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., & Vasic, V. M. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030006 · Cited by 2,611
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Pathology of Neurodegenerative Diseases
Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665 · cited 2×
“The reduced cognition aligns with a loss of neuronal transmission and functionality, as well as a loss of neuronal mass [5,6].”
BackgroundThe hippocampus and memory: insights from spatial processing
Bird, C. M., & Burgess, N. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2335 · Cited by 1,313 · cited 1×
“AD patients experience brain cortical atrophy primarily within the frontotemporal lobes, notably within the hippocampal and entorhinal cortex [5,6], consistent with the loss of cognitive function and memory attributed to these brain regions [7].”
BackgroundTerry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159 · cited 1×
“A reduction of signaling from the neurotransmitter acetylcholine (ACh) led to the concept of a “cholinergic hypothesis” to explain some of the cognitive deficits experienced by AD patients [8,9].”
BackgroundThe cholinergic system in aging and neuronal degeneration
Schliebs, R., & Arendt, T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.11.058 · Cited by 1,047 · cited 1×
“A reduction of signaling from the neurotransmitter acetylcholine (ACh) led to the concept of a “cholinergic hypothesis” to explain some of the cognitive deficits experienced by AD patients [8,9].”
BackgroundBurns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829 · cited 2×
“This is particularly pertinent for tacrine, given that excessive ADRs were responsible for its removal from the drug market [36,38].”
BackgroundEncinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Ceña, V., Gallego, C., & Comella, J. X. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750991.x · Cited by 820
Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588 · cited 1×
“One approach to provide suitable drug efficacy to treat AD, but at a lower dosing regimen, is via combination drug therapy [23].”
BackgroundCheung, Y.-T., Lau, W. K.-W., Yu, M.-S., Lai, C. S.-W., Yeung, S.-C., So, K.-F., & Chang, R. C.-C. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2008.11.001 · Cited by 576
Agholme, L., Lindström, T., Kågedal, K., Marcusson, J., & Hallbeck, M. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091363 · Cited by 498
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer’s disease
Frisoni, G. B., Laakso, M. P., Beltramello, A., Geroldi, C., Bianchetti, A., Soininen, H., & Trabucchi, M. (1999) · Neurology · doi:10.1212/wnl.52.1.91 · Cited by 285 · cited 2×
“The reduced cognition aligns with a loss of neuronal transmission and functionality, as well as a loss of neuronal mass [5,6].”
BackgroundStructure-Based Search for New Inhibitors of Cholinesterases
Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C., & Malawska, B. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14035608 · Cited by 274 · cited 1×
“The catalytic region of AChE (the esteratic site) is located at the bottom of a narrow gorge and contains three essential amino acids that provide the catalytic triad [24,40].”
BackgroundA Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Perrier, A. L., Massoulié, J., & Krejci, E. (2002) · Neuron · doi:10.1016/s0896-6273(01)00584-0 · Cited by 248
de Medeiros, L. M., De Bastiani, M. A., Rico, E. P., Schonhofen, P., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Grun, L., Barbé-Tuana, F., Zimmer, E. R., Castro, M. A. A., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1605-3 · Cited by 246
National Institute for Health and Care Excellence (NICE)
(2018) · The Grants Register 2018 · doi:10.1007/978-1-349-94186-5_836 · Cited by 226
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217 · cited 1×
“The FDA approved concomitant use of memantine and ChEIs has primarily proved clinical efficacious and comparable to monotherapies, and for some studies provided additional benefit of reduced neurobehavioral symptoms [48].”
BackgroundRydberg, E. H., Brumshtein, B., Greenblatt, H. M., Wong, D. M., Shaya, D., Williams, L. D., Carlier, P. R., Pang, Y.-P., Silman, I., & Sussman, J. L. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060164b · Cited by 190
Jabir, N. R., Khan, F. R., & Tabrez, S. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12971 · Cited by 187
Cholinesterase inhibitors in the treatment of dementia.
Ellis, J. M. (2005) · PubMed · Cited by 186
Berberine: A Potential Multipotent Natural Product to Combat Alzheimer’s Disease
Ji, H.-F., & Shen, L. (2011) · Molecules · doi:10.3390/molecules16086732 · Cited by 166
The combination index (CI < 1) as the definition of synergism and of synergy claims
Chou, T.-C. (2018) · Synergy · doi:10.1016/j.synres.2018.04.001 · Cited by 164 · cited 1×
“CI values below that line are indicative of synergism (CI < 1), and CI values above the line represent antagonism (CI > 1) [31].”
BackgroundRole of berberine in Alzheimer’s disease
Cai, Z., Wang, C., & Yang, W. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s114846 · Cited by 159
Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research
Ye, M., Fu, S., Pi, R., & He, F. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp/61.07.0001 · Cited by 121
Cholinesterase inhibitors from botanicals
Ahmed, F., Ghalib, R. M., Sasikala, P., & Ahmed, K. M. (2013) · Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review · doi:10.4103/0973-7847.120511 · Cited by 121
Shan, W., Huang, L., Zhou, Q., Meng, F.-C., & Li, X. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.051 · Cited by 89
Snape, M., Misra, A., Murray, T. K., Souza, R. J. D., Williams, J. L., Cross, A. J., & Green, A. R. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(98)00164-6 · Cited by 85 · cited 2×
“Substrate (AChE) binding by a ChEI may be to a similar site [39], but AChE can potentially accommodate two ChEI molecules simultaneously.”
BackgroundThe mass-action law based algorithms for quantitative econo-green bio-research
Chou, T. (2011) · Integrative Biology · doi:10.1039/c0ib00130a · Cited by 79 · cited 1×
“Drug concentrations were prepared according to Supplementary Table S1 [28].”
MethodDonepezil Inhibits Acetylcholinesterase via Multiple Binding Modes at Room Temperature
Silva, M. A., Kiametis, A. S., & Treptow, W. L. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b01073 · Cited by 71
Nwidu, L. L., Elmorsy, E. M., Aprioku, J. S., Siminialayi, I., & Carter, W. G. (2018) · Medicines · doi:10.3390/medicines5030071 · Cited by 69
Self-citationGreen, C., Picot, J., Loveman, E., Takeda, A., Kirby, J. C., & Clegg, A. J. (2005) · PharmacoEconomics · doi:10.2165/00019053-200523120-00010 · Cited by 61
Nwidu, L. L., Elmorsy, E. M., Thornton, J., Wijamunige, B. C., Wijesekara, A., Tarbox, R., Warren, A. Y., & Carter, W. G. (2017) · Pharmaceutical Biology · doi:10.1080/13880209.2017.1339283 · Cited by 60
Self-citationPotential Nutraceutical Properties of Leaves from Several Commonly Cultivated Plants
Amat-ur-Rasool, H., Symes, F., Tooth, D., Schaffert, L.-N., Elmorsy, E. M., Ahmed, M., Hasnain, S., & Carter, W. G. (2020) · Biomolecules · doi:10.3390/biom10111556 · Cited by 59
Self-citationPharmacokinetics of tacrine hydrochloride in Alzheimer's disease
Forsyth, D. R., Wilcock, G. K., Morgan, R. A., Truman, C. A., Ford, J. M., & Roberts, C. J. C. (1989) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1989.199 · Cited by 58
Kröger, E., Mouls, M., Wilchesky, M., Berkers, M., Carmichael, P.-H., van Marum, R., Souverein, P., Egberts, T., & Laroche, M.-L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015602274 · Cited by 58
Mak, S., Luk, W. K. W., Cui, W., Hu, S., Tsim, K. W. K., & Han, Y. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0288-5 · Cited by 56
Blotnick, E., & Anglister, L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00123 · Cited by 44 · cited 1×
“inhibit the activity of acetylcholinesterase (AChE), which is predominantly localized to the pre-synaptic membrane in the CNS and the synaptic basal lamina of the neuromuscular junction [13,14].”
BackgroundKong, X., Liu, E. Y. L., Chen, Z.-C., Xu, M. L., Yu, A. X., Wu, Q., Xia, Y., Duan, R., Dong, T. T.-X., & Tsim, K. W. K. (2019) · Molecules · doi:10.3390/molecules24244567 · Cited by 41
Amat-ur-Rasool, H., & Ahmed, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136509 · Cited by 33 · cited 1×
“The catalytic region of AChE (the esteratic site) is located at the bottom of a narrow gorge and contains three essential amino acids that provide the catalytic triad [24,40].”
BackgroundSelf-citationDocking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase
Stavrakov, G., Philipova, I., Zheleva‐Dimitrova, D., Atanasova, M., Konstantinov, S., & Doytchinova, I. A. (2016) · Molecular Informatics · doi:10.1002/minf.201600041 · Cited by 28
Lou, G., Montgomery, P. R., & SITAR, D. S. (1996) · PubMed Central · Cited by 22
Li, S., Huang, R., Solomon, S., Liu, Y., Zhao, B., Santillo, M. F., & Xia, M. (2017) · Biotechnology Journal · doi:10.1002/biot.201600715 · Cited by 15 · cited 1×
“The cell-based Ellman’s assay described by Li et al. (2017) [29] was modified for 6-well plates.”
MethodNwidu, L. L., Alikwe, P. C. N., Elmorsy, E. M., & Carter, W. G. (2019) · Medicines · doi:10.3390/medicines6010015 · Cited by 13
Self-citation
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer’s Disease
Vrabec, R., Blunden, G., & Cahlíková, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054399 · Cited by 53
“The common source for in vitro tests with AChE is an eel, Electrophorus electricus (EeAChE), which, however, can provide divergent results in comparison to human AChE (hAChE) [7,20].”
BackgroundApplication of Marine Natural Products against Alzheimer’s Disease: Past, Present and Future
Hu, D., Jin, Y., Hou, X., Zhu, Y., Chen, D., Tai, J., Chen, Q., Shi, C., Ye, J., Wu, M., et al. (2023) · Marine Drugs · doi:10.3390/md21010043 · Cited by 53
“Thus, it could be used for new treatment of AD in the body from the view of barrier of blood-brain [55].”
BackgroundTherapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 41
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., Ahmed, A., & Carter, W. G. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb44010012 · Cited by 31
Self-citation
Metadata
- Authors
- Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G.
- Affiliations
- University of Nottingham (GB)
- University of the Punjab (PK)
- Corresponding author
- Carter, Wayne G.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2021-02-02
- Volume
- 11
- Issue
- 2
- Pages
- 184
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC7913148
- OpenAlex
- W3128108545
- Cited by
- 43
- References
- 51
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 4
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Higher Education Commision, Pakistan (315-78152BS3-096, IRSIP No.1-8 /HEC/ HRD/2018/8570), NRPU Grant 8288)
- Commonwealth Scholarship Commission (PKCN-2018-267)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pesticide Exposure and Toxicity
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, combination therapy, acetylcholinesterase inhibition, donepezil, tacrine, berberine, galantamine, synergistic effect, antagonism, adverse drug reactions, neurons, Torpedo californica acetylcholinesterase, drug toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.